First-line Treatment of Locally Advanced HNSCC with Double Checkpoint Inhibition and Radiotherapy Based on CD8+ T Cell Infiltration.

Introduction In this open-label Phase II study, patients with stage III-IVB received an induction cycle of combined chemo-immunotherapy with cisplatin / docetaxel plus durvalumab / tremelimumab. The number of CD8 cells in tumor and peritumoral tissue was determined on biopsies before and after chemo-induction therapy. With an increase in CD8 cells, immunotherapy was continued with radiation.